Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.34 |
| ▸ | KDR | P35968 | 8/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22075333 | 0.88 | TNIK (0.39) | ACVR1TGFBR1METROCK2MAPK14 | |
| SCHEMBL25085169 | 0.83 | TGFBR1 (0.44) | ACVR1TGFBR1FGFR3KDRFGFR1 | |
| SCHEMBL22075150 | 0.82 | ADORA3 (0.33) | TGFBR1FGFR3KDRMAPK14 | |
| SCHEMBL30396567 | 0.82 | ADORA3 (0.33) | TGFBR1FGFR3KDRMAPK14 | |
| SCHEMBL30579208 | 0.81 | FGFR3 (0.39) | METFGFR3KDRFGFR1FGFR2 | |
| SCHEMBL22075038 | 0.81 | FGFR3 (0.39) | METFGFR3KDRFGFR1FGFR2 | |
| SCHEMBL22075131 | 0.77 | WNT1 (0.37) | FGFR3KDRMAPK14 | |
| SCHEMBL30579262 | 0.77 | FGFR3 (0.40) | METFGFR3KDRFGFR1FGFR2 | |
| SCHEMBL22075160 | 0.77 | FGFR3 (0.40) | METFGFR3KDRFGFR1FGFR2 | |
| SCHEMBL22075393 | 0.76 | SCN9A (0.38) | FGFR3KDRSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10952996-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-10952996-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200188370-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200188370-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952996-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | ACVR1 2/4885TGFBR1 97/4885MET 105/4885 |
| US-20210154178-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | ACVR1 2/4885TGFBR1 97/4885MET 105/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | ACVR1 2/4885TGFBR1 97/4885MET 105/4885 |
| US-20200188370-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | ACVR1 2/4885TGFBR1 97/4885MET 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.